series-a
Stage
2
Investors
About
Rappta Therapeutics is a late preclinical stage biopharmaceutical company focused on developing anti-cancer molecular glues that reactivate the tumor suppressor protein phosphatase 2A (PP2A). The company utilizes proprietary technology to target PP2A, a critical enzyme involved in regulating protein de-phosphorylation and tumor growth.
Explore Rappta Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.